In8bio, INC Form 4 insider transactions

Director Emily Fairbairn reported a gift of 724,637 shares of IN8bio common stock to a charitable foundation.

IN8BIO, INC. CEO William Ho receives a stock option grant for 154,500 shares, with vesting scheduled over four years.

IN8BIO, INC. reports that Director Luba Greenwood acquired 22,000 stock options with an exercise price of $1.58, vesting monthly starting June 9, 2026.

IN8BIO, Inc. reports that EVP and CSO Lawrence Lamb acquired 54,000 employee stock options with an exercise price of $1.58.

IN8BIO, Inc. reports that Director Emily Fairbairn acquired 22,000 stock options with an exercise price of $1.58, vesting over time.

IN8BIO, INC. Chief Financial Officer Patrick McCall was granted employee stock options for 56,250 shares of common stock.

IN8BIO, INC. reports a Form 4 filing detailing the grant of stock options to Director Corinne Epperly.

Kate Rochlin, President and COO of IN8BIO, Inc., was granted 60,000 employee stock options with an exercise price of $1.58.

IN8BIO's Executive Vice President and Chief Scientific Officer, Lawrence Lamb, was granted 72,000 employee stock options with an exercise price of $1.96.

IN8BIO's Chief Financial Officer, Patrick McCall, was granted 75,000 employee stock options with an exercise price of $1.96.

IN8BIO's President and COO, Kate Rochlin, was granted 80,000 employee stock options with an exercise price of $1.96, vesting over four years.

IN8BIO's CEO, William Tai-Wei Ho, was granted 206,000 employee stock options with an exercise price of $1.96, vesting over four years.

IN8BIO's Chief Operating Officer, Kate Rochlin, acquired 7,247 shares of common stock at $1.38 per share, adjusted for a recent 1-for-30 reverse stock split, under a pre-arranged 10b5-1 plan.

IN8BIO's Chief Financial Officer, Patrick McCall, acquired 7,247 shares of common stock at $1.38 per share, increasing his direct beneficial ownership to 9,482 shares, following a recent reverse stock split.

IN8BIO's President and CEO, William Tai-Wei Ho, acquired 36,232 shares of common stock at $1.38 per share, increasing his beneficial ownership.

IN8BIO Director Alan S. Roemer acquired 36,232 shares of common stock at $1.38 per share, bringing his total beneficial ownership to 49,514 shares, adjusted for a recent 1-for-30 reverse stock split.

IN8BIO Director Peter C. Brandt acquired 72,464 shares of common stock at $1.38 per share, increasing his beneficial ownership.

IN8BIO Director Emily Fairbairn reported an acquisition of 724,637 common shares at $1.38 per share, increasing her indirect beneficial ownership.

Director Corinne Epperly reports acquisition of stock options in IN8BIO, INC.

Director Peter C. Brandt acquired stock options in IN8BIO, INC. on May 8, 2025, according to a Form 4 filing.

Director Alan S. Roemer of IN8BIO, INC. reports the acquisition of stock options.

Director Luba Greenwood reports acquisition of stock options in IN8BIO, INC.

Director Jeremy R. Graff reports acquisition of stock options in IN8BIO, INC.

Director Emily Fairbairn acquired stock options in IN8BIO, INC. on May 8, 2025.

Bios Clinical Opportunity Fund acquired pre-funded warrants from In8bio in exchange for the surrender of existing warrants and a cash payment, resulting in changes in beneficial ownership for several reporting persons.

Bios Clinical Opportunity Fund exchanges existing warrants for pre-funded warrants and cash in a private placement with In8bio, Inc., resulting in adjustments to beneficial ownership by related entities and individuals.

Lawrence Lamb, EVP and CSO of IN8BIO, INC., amended the terms of outstanding Series B warrants, reducing the exercise price from $1.50 to $0.45 per share.

Director Jeremy R. Graff reports an amendment to outstanding warrants of IN8BIO, Inc., resulting in a reduced exercise price from $1.50 to $0.45 per share.

Corinne Epperly, a director at IN8BIO, INC., amended the terms of outstanding warrants, reducing the exercise price from $1.50 to $0.45 per share.

IN8BIO CEO William Tai-Wei Ho amended existing warrants and acquired pre-funded warrants to purchase common stock, according to a recent SEC filing.